P515: LOWER-INTENSITY CPX-351 + VENETOCLAX FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY

• G. L. Uy,
• V. A. Pullarkat,
• P. Baratam,
• R. K. Stuart,
• R. B. Walter,
• E. S. Winer,
• S. Faderl,
• V. Chandrasekaran,
• Q. Wang,
• D. Chakravarthy,
• R. S. Cheung,
• T. L. Lin

Affiliations

G. L. Uy

1 Washington University School of Medicine, St. Louis, MO

V. A. Pullarkat

2 City of Hope Comprehensive Cancer Center, Duarte, CA

P. Baratam

3 Medical University of South Carolina, Charleston, SC

R. K. Stuart

3 Medical University of South Carolina, Charleston, SC

R. B. Walter

4 Fred Hutchinson Cancer Research Center, Seattle, WA

E. S. Winer

5 Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

S. Faderl

6 Jazz Pharmaceuticals, Palo Alto, CA

V. Chandrasekaran

6 Jazz Pharmaceuticals, Palo Alto, CA

Q. Wang

6 Jazz Pharmaceuticals, Palo Alto, CA

D. Chakravarthy

6 Jazz Pharmaceuticals, Palo Alto, CA

R. S. Cheung

6 Jazz Pharmaceuticals, Palo Alto, CA

T. L. Lin

7 University of Kansas Medical Center, Kansas City, KS, United States of America